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The aim of this study was to evaluate the activity of gamma interferon (IFN-) when it was either adsorbed
onto or loaded into albumin nanoparticles. Brucella abortus-infected macrophages and infected BALB/c mice
were selected as the models for testing of the therapeutic potentials of these cytokine delivery systems, in view
of the well-established role of IFN--activated macrophages for the control of Brucella sp. infections. Whereas
the encapsulation of IFN- inside the matrix of nanoparticles completely abrogated its activity, adsorbed
IFN- increased by 0.75 log unit the bactericidal effect induced by RAW macrophages activated with free
IFN-, along with a higher level of production of nitric oxide. In infected BALB/c-mice, IFN- adsorbed onto
nanoparticles was also more active than free cytokine in reducing the number of bacteria in the spleens, and
the effect was mediated by an increased ratio of IFN--secreting (Th1) to interleukin-4-secreting (Th2) cells.
Overall, albumin nanoparticles would be suitable as carriers that target IFN- to macrophages and, thus,
potentiate their therapeutic activity.
Malfunction of the host defense system renders patients
more susceptible to opportunistic infections and can make
antibiotic treatment ineffective (15). Activation of cells of the
mononuclear phagocyte system, in particular, resident macro-
phages, by immunomodulating agents has been proved to be
beneficial in several infection models (3, 7, 14, 18) and in
antitumor therapy (10, 17).
Among them, gamma interferon (IFN-) is an important com-
ponent of the Th1-type cellular immune response and contributes
to the control of bacteria through its ability to activate macro-
phages to increase microbial killing (23, 24). Using an experimen-
tal model with Brucella abortus-infected mice, Zhan and Cheers
(33) showed that host resistance against these bacteria was pri-
marily mediated by activated macrophages and also by a Th1
profile (4). Also, there is a correlation between host control over
parasite replication and the capacity of T cells to produce IFN-
(11). However, the therapeutic potential of IFN-may be limited
by its rapid clearance from the circulation and, thus, a brief du-
ration of the activating effect on macrophages. This fact implies
that frequent and high doses, which often result in severe systemic
side effects, must be used (32).
In order to improve the therapeutic indices of these macro-
molecules, one possibility may consist of the use of delivery
systems able to both maintain appropriate levels in blood for
long periods of time and target the cytokine to macrophages,
the reservoir for those microorganisms (1). IFN- targeting
with colloidal systems, such as liposomes and microparticles,
has led to both a reduction in toxicity and an increase in the
efficacy of IFN- against a great variety of intracellular para-
sites, such as Leishmania donovani (5) and Klebsiella pneu-
moniae (28). IFN- loaded into liposomes was also effective as
an adjuvant with antiviral vaccines (30) and antitumor vaccines
(31). Another interesting approach that could increase the
therapeutic efficiency of IFN- may be to load it into albumin
nanoparticles (IFN-–NPs). In fact, we have previously re-
ported that these carriers have a high payload of IFN-. More
importantly, they retain integrity, one of the handicaps cur-
rently found during the development of delivery systems for
cytokines (26).
On the basis of the deeply understood role of IFN- in the
fight against infections caused by Brucella spp. (12, 22), we
chose experimental infection of RAW macrophages and of
BALB/c mice with this pathogen as suitable models for eval-
uation of the effectiveness of NPs in potentiating the immu-
nomodulatory activities of IFN-. Also, the contributions of
NO production in vitro and the Th1 response in vivo in the
antibrucella effects were examined.
MATERIALS AND METHODS
Materials. Recombinant human and mouse IFN- with a specific activity of
1.0  107 UI/mg and IFN- enzyme-linked immunosorbent assay (ELISA) kits
were obtained from Biosource International. Bovine serum albumin (BSA; frac-
tion V), concanavalin A (ConA), and glutaraldehyde (25%; grade II) were
obtained from Sigma Chemical Co. (St Louis, MO). Absolute ethanol and
chlorhydric acid were purchased from Prolabo (Fontenay, France). Sodium ni-
trite was obtained from Merck (Darmstadt, Germany). Dulbecco modified Eagle
medium (DMEM), fetal bovine serum, and L-glutamine were obtained from
Gibco-BRL.
NP preparation and characterization. BSA nanoparticles (NPs) were pre-
pared by coacervation and chemical cross-linkage with glutaraldehyde, as de-
scribed previously (26). Depending on the step in which the cytokine was added,
two different formulations were prepared. In the former, 1 g IFN-/mg BSA
was incubated with the albumin NPs (IFN-–NPAs). In the latter, both the
protein and the cytokine (1 g IFN-/mg BSA) were incubated in an aqueous
medium prior the formation of the NPs by coacervation (IFN-–NPBs).
Briefly, IFN-–NPAs were obtained by the addition of 1.5 ml of ethanol
dropwise (ethanol-to-water ratio, 1.5:1, by volume) to 1 ml of an aqueous solu-
tion of BSA (2% [wt/vol]), adjusted to pH 5.5 with 0.1 N HCl. The coacervates
thus obtained were then hardened with glutaraldehyde that had previously been
dissolved in ethanol (1.56 g/mg bulk albumin) for 2 h at room temperature.
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After ethanol elimination by evaporation under reduced pressure (water bath
B-480; Buchi, Switzerland), the NPs were purified by centrifugation at 17,000
rpm for 30 min (rotor 3336; Biofuge Heraeus, Hanau, Germany) to eliminate the
free albumin and the excess of the cross-linking agent. The supernatants were
removed and the empty NPs were resuspended in an aqueous solution containing
IFN- for incubation for 0.5 h. Finally, the IFN-–NPAs were separated from the
free cytokine by centrifugation (17,000 rpm/30 min) at 4°C.
For the preparation of IFN-–NPBs, IFN- was first incubated with the albu-
min aqueous solution (2% [wt/vol]; pH 5.5) for 0.5 h at room temperature. This
aqueous phase was then desolvated with ethanol dropwise (ethanol-to-water
ratio, 1.5:1. by volume). The coacervates so formed were then hardened with
glutaraldehyde that had previously been dissolved in ethanol (1.56 g/mg bulk
albumin) for 2 h at room temperature, and the resulting NPs were purified by
centrifugation as described above. In all cases, the NPs purified by centrifugation
were resuspended and dispersed in phosphate-buffered saline (PBS).
The average particle size, polydispersity index, and zeta potential of the NPs
were determined with a Nanosizer ZS (Malvern Instruments, United Kingdom),
after appropriate dilution in double-distilled water.
The amount of protein transformed into NPs was determined by a standard
bicinchoninic acid protein assay. The IFN- load was determined by ELISA. For
this purpose, aliquots of the clear supernatants obtained during the purification
of the NPs were analyzed for IFN- content. The amount of the cytokine was
estimated from the difference between the amount initially added and the re-
covered amount in the supernatants. The IFN- load was expressed as the ratio
between the amount of cytokine in the NPs (expressed in g) and the NPA yield
(expressed in mg).
Bacteria. Brucella abortus strain 2308, a virulent field strain, was used in all
studies. It was grown on tryptic soy agar for infection for 24 h at 37°C.
Cell culture. The murine macrophage cell line RAW 264.7 was obtained from
ATCC. RAW 264.7 cells were maintained in DMEM supplemented with 10%
heat-inactivated fetal bovine serum, 50 g of L-glutamine per ml, 50 IU of
penicillin per ml, and 50 g of streptomycin per ml.
In vitro infection assay. RAW 264.7 cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum at 105 cells per well. Macrophages
seeded at this concentration were incubated with the different IFN- formula-
tions at a cytokine concentration of 100 IU/ml for 24 h before they were infected.
A control culture, which never received IFN-, was also established in parallel.
Then, 100 l of antibody-opsonized bacteria, suspended to the appropriate
concentration in DMEM, was added to each well at a bacterium-to-macrophage
ratio of 100:1. The microwell plates containing the macrophages and the bacteria
were centrifuged at 200  g at 4°C for 5 min to increase the attachment of B.
abortus to macrophages and were then incubated at 37°C for 1 h 50 min, as
described previously (12).
To avoid the loss of the macrophages, which became less adherent after
infection or cytokine treatment, the macrophage cultures were centrifuged at
200  g between supernatant treatments.
Following the 2-h infection period, the majority of extracellular bacteria were
removed by washing the macrophage cultures three times with PBS, followed by
incubation for 1 h in DMEM containing 50 g gentamicin per ml (time zero of
the culture). Following the wash procedure, one set of cultures was treated again
with the IFN- formulations with a cytokine concentration of 100 IU/ml for a
further 24 h.
The infected cells were lysed by pipetting with 200 l of 0.1% Triton X-100 in
PBS. To enumerate the viable intracellular Brucella, cell lysates were diluted and
plated on Brucella agar. The numbers of bacterial CFU were counted after a
3-day incubation at 37°C with 5% CO2 in air, and the numbers of CFU were
transformed to log10.
NO2
 measurements. The culture cell-free supernatants were assayed for the
accumulation of NO2 by the Griess reaction. The determinations were done
after the pretreatment but before the infection and after the treatment and
postinfection.
Animals. Female BALB/c mice were purchased at 6 to 8 weeks of age and were
used at 8 to 10 weeks of age. The animal experiments were performed in
compliance with the regulations of the responsible committee of the University
of Navarra, in line with the European legislation on animal experiments (86/609/
EU). All mice were housed in biohazard level 3 facilities in microisolator cages
and were handled under sterile conditions, including sterile food, water, cages,
breeding conditions, and handling of the animals by laboratory personnel.
In vivo infection assay. The mice were infected intraperitoneally with a sus-
pension of 104 CFU of B. abortus in 0.2 ml of PBS. Treatment of the mice (five
mice per group) with single doses of IFN- formulations and free IFN- at
10,000 IU per day was done intraperitoneally at 1 day before infection and again
at 2 and 4 days after infection.
At 1 week (three mice per group) and 2 weeks (two mice per group) postin-
fection, the mice were killed by cervical dislocation, and their spleens were
removed and homogenized in plastic bags with 10 ml of sterile PBS by using a
stomacher lab blender, and the numbers of CFU were determined.
In vitro cytokine release. The spleens from the mice were placed in RPMI
1640 medium and smashed in tissue culture dishes (Iwaki, Japan), and the fat
and the capsule were removed. Spleen cells from within experimental groups
were mixed in one flask and centrifuged at 400  g and 4°C for 8 min. The
supernatants were discarded, and the pellet was washed twice with PBS and
centrifuged at 400  g and 4°C for 8 min. Then, the spleen cell suspensions were
incubated in lysis buffer (NH4Cl, 0.15 M; KHCO3, 1 mM; EDTA, 0.1 mM; pH 7.2
to 7.4) for 3 min to lyse the erythrocytes and refilled with RPMI 1640 medium to
stop the reaction. The resulting suspensions were centrifuged at 1,500 rpm and
4°C for 5 min and resuspended in complete medium (RPMI 1640 medium
supplemented with 2 l 2-mercaptoethanol, 500 U penicillin, 500 g streptomy-
cin, 10 mM HEPES, and 10% heat-inactivated fetal calf serum).
For in vitro cytokine release, isolated splenocytes (8  105/well) were seeded
into a 24-well plate and stimulated with 0 and 5 g/well of ConA for 48 h at 37°C.
The cytokines (interleukin-4 [IL-4] and IFN-) in the supernatant were quanti-
fied by using ELISA kits from Biosource.
Statistical analysis of results. All experiments were repeated at least three
times. The results were expressed as means  standard deviations. Uptake data
were analyzed by one-way analysis of variance, with the post-hoc Tukey’s test
applied for comparisons of several (three or more) group means (SPSS 10; SPSS
Inc., Chicago, IL). A P value of 0.05 was considered significant.
RESULTS
Characterization of IFN-–NPs. Table 1 shows the main
physicochemical characteristics of the different IFN-–NP for-
mulations prepared with an IFN--to-albumin ratio of 1 g/
mg. Both types of NPs displayed a size of about 330 nm. The
amount of IFN- loaded into the NPs was very high for both
procedures of preparation, either by the encapsulation process
(IFN-–NPBs) or by simple adsorption of the cytokine onto
preformed NPs (IFN-–NPAs).
Macrophage bactericidal activity against B. abortus. RAW
264.7 macrophages were incubated with free IFN- or the
IFN- formulations before and, eventually, after infection or
before infection only (Fig. 1).
When IFN- was adsorbed onto the IFN-–NPAs, the total
reduction of intracellular bacteria was about 2 log CFU rela-
tive to the amount in the untreated cells (P  0.05) and 1 log
CFU relative to the amount for macrophages treated with free
IFN- (P  0.05) when the cells were treated either only
before infection or also after infection. Unloaded NPs and NPs
encapsulating the cytokine inside their matrix (IFN-–NPBs)
did not show antibrucellae activities.
NO production in infected RAW 264.7 cells. Both NO and
reactive oxygen intermediates mediate macrophage anti-Bru-
cella effects. To examine the role of NO in IFN--mediated
anti-Brucella activity, the NO accumulation in infected-cell su-
pernatants was measured.
TABLE 1. Physicochemical characteristics of albumin nanoparticles
contaning IFN-a
IFN-
formulation
Size
(nm)
Zeta
potential
(mV)
Drug loading
(g IFN-/mg NP)
Entrapment
efficiency (%)
IFN-–NPA 339  7 19.6  0.5 1.0  0.3 83.2  0.8
IFN-–NPB 326  3 40.9  0.5 1.2  0.1 99.9  1.4
a Experimental conditions included an IFN-/BSA ratio of 1 g/mg. Data are
expressed as the means  standard deviations of three experiments. Three
measurements were performed in each experiment (n  9).
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The infection of macrophages with B. abortus increased their
levels of NO production. Table 2 summarizes these results.
The addition of free IFN- to macrophages cultured without
Brucella enhanced NO production (8-fold), and this produc-
tion was fairly enhanced (P  0.05) when macrophages were
cultured with IFN- adsorbed onto NPs (11-fold). When the
cells were infected with Brucella and treated with free IFN- or
IFN-–NPAs, the level of NO production also increased about
fourfold. In any case, the IFN-–NPA formulation was found
to be the best formulation for the induction of NO production
by the RAW 264.7 macrophages (P  0.05). In contrast, neg-
ligible levels were observed when IFN- was incorporated into
the NPs. Empty NPs also showed no effect on the activation of
macrophages.
Resistance of mice to infection with B. abortus. Table 3
shows that the treatment of mice with IFN- at 1 day before
infection and again at 2 and 4 days after infection with B.
abortus did not significantly alter the number or the growth of
intracellular brucellae either 1 or 2 weeks after infection. How-
ever, macrophages treated with IFN-–NPAs reduced by
about 1 log the number of intracellular bacteria relative to the
amount in untreated mice (P  0.05) both 1 and 2 weeks after
infection. Finally, neither unloaded NPs nor IFN-–NPBs had
any effect on the infection rate.
Additionally, the weights of the spleens of noninfected mice
treated with IFN- and IFN--containing NPs (Table 3) indi-
cated an increase in the proliferative response induced by the
cytokine when it was administered in association with NPAs.
Brucella infection induced an inflammatory response that pre-
vented the analysis of the proliferation induced by the formu-
lations with infected mice.
IFN- and IL-4 production in infected mice. Figure 2 shows
the data for the amount of IFN- released from isolated
splenocytes after in vitro stimulation with ConA. The treat-
ment of splenocytes from mice with free IFN- led to signifi-
cantly enhanced IFN- release in response to ConA compared
to that for the control cells (P  0.05). Again, the splenocytes
isolated from mice treated with IFN-–NPA released the larg-
est amount of IFN- after stimulation (P  0.05). In contrast,
IFN-–NPBs and empty NPs produced relatively low levels of
IFN-.
On the other hand, the amount of IL-4 released from
splenocytes after stimulation with ConA was also measured. As
we can see in Fig. 2, high levels of IL-4 were detected from the
FIG. 1. Effects of IFN- and IFN- formulations on resistance to
Brucella abortus infection in RAW 264.7 macrophages. Brucella abor-
tus-infected RAW 264.7 macrophages were treated (IFN-, 100 IU/ml)
24 h before infection (black bars) or 24 h after infection (white bars).
Untreated control macrophages (control) and macrophages treated
with empty NPs were also used. Bars represent the mean  standard
deviation numbers of CFU for three wells in an experiment represen-
tative of three repetitions. a, P  0.05 relative to the results for the
control; b, P  0.05 relative to the results for mice treated with IFN-.
TABLE 2. Nitric oxid acumulation in supernatants of RAW 264.7
macrophages treated in vitro with IFN- formulationsa
Formulation
NO production (M)
I II
Basal 2.4 1.3 6.4  1.4
Empty NPs 5.0  1.3 8.9  1.0
IFN- 16.4  0.9 23.0  2.4
IFN-–NPA 22.4 2.1b 27.2  1.2b
IFN-–NPB 8.7 0.4 9.9  0.9
a The cells were incubated for 24 h with 100 IU/ml of IFN- formulations
before infection and were treated again at 24 h postinfection with the same dose.
The level of NO production was measured after the pretreatment but before the
infection (I) and after the treatment and postinfection (II). Data are expressed
as the means  standard deviations of three measurements in an experiment
representative of three repetitions (n  3).
b P  0.05 relative to the results for IFN-.
TABLE 3. Effects of IFN- and IFN- formulations on resistance
to Brucella abortus in micea
Formulation
CFU log10/spleen at the
following time after infection: Spleen wt (mg)
1 wk 2 wk
Control 5.2  0.1 5.0  0.2 125.0  15.0
NP 5.1  0.1 5.0  0.1 175.0  12.0b
IFN- 5.0  0.1 4.9  0.0 158.0  22.0b
IFN-–NPA 4.4 0.1b,c 4.3  0.1b,c 231.0  28.0b,c
IFN-–NPB 5.1 0.1 5.1  0.1 216.0  19.0b,c
a Mice received free IFN- or IFN- formulations at 104 IU/ml 24 h before
infection as well as 2 and 4 days after infection. The numbers of B. abortus CFU
per spleen were measured 1 and 2 weeks after infection. The spleen weights refer
to the effects in control (noninfected) mice after 1 week following treatment with
the IFN- formulations. Data are expressed as the means  standard deviations
of three experiments with three mice per group (1 week after infection; n  9)
or two mice per group (2 weeks after infection; n  6).
b P  0.05 relative to the results for the control.
c P  0.05 relative to the results for mice treated with IFN-.
FIG. 2. IFN- and Il-4 production by spleen cells from BALB/c
mice infected 1 week previously with 5  104 cells of B. abortus 2308.
Data are expressed as the means  standard deviations of three ex-
periments (n  3). In each experiment, the cells within experimental
groups (three mice per group) were pooled. a, P  0.05 relative to the
results for the control; b, P  0.05 relative to the results for mice
treated with IFN-.
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splenocytes of mice treated with IFN- or IFN-–NPAs com-
pared with that detected from the splenocytes of the control
mice (P  0.05). IFN-–NPBs and empty NPs produced levels
similar to those produced by the control.
DISCUSSION
The rationale for the present study is the direct targeting of
IFN- to its main site of action, the macrophages, by means of
the association of the cytokine with drug delivery systems, such
as NPs. The strategy could protect the cytokine from rapid
enzymatic degradation and clearance and then improve the
activities of the cytokines at lower doses, which would allow
their toxicity to be avoided (32). A gross body of evidence from
previous reports has evidenced the benefits of targeting anti-
microbial agents directly to macrophages through their asso-
ciation with lipidic or polymeric particles (2, 16). Also, among
the different kinds of delivery systems, albumin NPs are espe-
cially suitable for the encapsulation of biomolecules with high
sensitivities to media and structural requirements, such as cy-
tokines. The experimental conditions for the optimal associa-
tion of IFN- with NPs have been reported previously (26). We
prepared two types of IFN delivery systems. In one of them,
IFN-–NPAs, the cytokine was adsorbed onto preformed NPs.
In IFN-–NPBs, IFN- readily encapsulated into the matrix of
the particles by binding to the albumin prior to the NP forma-
tion process. Both the IFN-–NPAs and the IFN-–NPBs had
a mean size distribution (about 300 nm) suitable for their
optimal uptake by phagocytic cells, such as macrophages. Ma-
jor differences were related to the cytokine release profile. As
determined by a bioassay, meanwhile, IFN-–NPAs released
80% of the loaded cytokine after 20 h; no release of cytokine
was detected from IFN-–NPBs after this incubation time (26).
The aim of the present work was to evaluate the activities of
both IFN- delivery systems against Brucella abortus in in-
fected macrophages and mice, which were used as models of
infective disease.
The ability of phagocytes to kill intracellular Brucella is de-
pendent on the Th1 subset of CD4 T cells, which secrete
IFN- in response to antigen. In the current study, we found
that in vitro, the pretreatment of RAW 264.7 macrophages
with 100 IU/ml of IFN- for 24 h resulted in an increased
ability of the macrophages to kill B. abortus (Fig. 1). The
greatest difference in killing potential was observed when
IFN- was added both before and after infection. In this way,
Jiang and Baldwin (12) showed that the pretreatment of J774.2
macrophages with 100 IU/ml of IFN- and the addition of
IFN- again after the infection resulted in more effective treat-
ment.
Whereas IFN-–NPAs were more effective than the free
cytokine for the prevention and eradication of the infection
(about 0.75 log of CFU reduction relative to that for macro-
phages treated with free IFN-), the cytokine encapsulated
into the NPs (IFN-–NPBs) did not show any effect. The ab-
sence of release of the cytokine from IFN-–NPBs (26) could
be the cause for this lack of effectiveness, in agreement with
the findings of similar studies performed with IFN- adsorbed
onto and/or encapsulated in liposomes (29). So far, the good
correlation between the amounts of NO released by macro-
phages activated with the different IFN- formulations and the
decrease in the number of colonies corroborate a decisive role
of NO from macrophages as the mediator of the killing of
intracellular Brucella spp., as described previously (8, 9, 13, 21).
Finally, our formulations were tested in vivo. BALB/c mice
were treated with IFN- 1 day before and again 2 and 4 days
after infection with B. abortus, but the treatment was not ef-
fective either 1 or 2 weeks after infection. The higher doses
administered by other authors could explain a certain amount
of the activity reported 1 week after infection (6). Anyway, this
effect was transient and it was not observed for periods of time
longer than 1 week (19, 20). The adsorption of IFN- onto NPs
(IFN-–NPAs) not only made the cytokine effective at this low
dose but also increased the duration of the effect, that is, for
almost 2 weeks. In this way, van Slooten et al. (29) showed that
IFN--loaded liposomes were active against influenza virus
infection 3 weeks after infection, while IFN- showed efficacy
only during the first week of treatment. This greater efficiency
can be due to the NPs that actually reach the infection site
before their degradation, with the IFN- then gradually de-
sorbed close to the parasites. In that sense, mice treated with
NPs containing IFN- showed significantly increased spleen
weights, probably indicating a major accumulation of macro-
phages that engulfed the NPs in this organ and that were
armed to fight the parasite (25). The inflammatory response
induced by IFN- depends on the incubation time (27). At
short times, IFN- mediates a transiently increased spleno-
megaly indicative of an immunostimulatory response. One
week later, if the treatment is effective, the bacteria will be
cleared from spleens; and thus, a significant reduction in the
spleen weight will result (27).
The patterns for the splenic cytokines from the mice treated
with free or associated IFN- also confirmed the increased
activity of IFN- when it was loaded onto NPs. We found a
mixed response in mice treated with free IFN- and IFN-–
NPAs, with cells producing Th1 cytokines as well as cells se-
creting Th2 cytokines. However, the ratio of IFN- to IL-4 was
higher in spleen cells from IFN-–NPA-treated mice. This
switching in the type of response dominance correlated well
with the better resistance with this treatment and underscored
the protective role exerted by the cytokines IFN- and IL-2 in
the face of a Brucella infection (11).
In summary, the present study demonstrates the feasibility
and efficacy of targeting IFN- by means of BSA NPs. NP
delivery was found to enhance the nonspecific activation of
RAW 264.7 macrophages, resulting in an increase in the level
of NO production and the killing of Brucella. The efficacy of
IFN- in protecting mice against Brucella was also significantly
improved by its adsorption on NPs. In this study, brucellosis
was selected as a model only to test the potential therapeutic
activities of exogenous IFN- and to demonstrate that NP-
adsorbed IFN- was more active than the free cytokine against
Brucella in vitro and in vivo. Albumin NPs would be also
suitable for the coencapsulation of therapeutic agents when an
additional or synergistic effect of chemotherapeutics (i.e., con-
ventional antibiotic therapy) along with immune system com-
ponents is sought. The use of exogenous IFN- may accelerate
the response to conventional therapy; hence, the potential
applications for IFN- NPs may include not only infections
which typically respond poorly to available treatment or infec-
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tions which require prolonged therapy for cure but also long-
term prophylaxis in patients with T-cell-deficient states.
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